Introduction: Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of the BCR-ABL fusion gene, resulting from the t(9;22)(q34;q11) translocation, known as the Philadelphia chromosome. Although CML is more common in adults, cases in adolescence represent a diagnostic and therapeutic challenge. Detection of the BCR-ABL oncogene assists in confirming the disease and in monitoring therapeutic response. Understanding the distribution of these cases may contribute to strategies for diagnosis and management of the pathology. Objectives: To identify the frequency of BCR-ABL fusion gene transcripts in adolescent cases among patients suspected of CML treated at the HEMOPA Foundation. Methods: The project was previously approved by the Research Ethics Committee (CEP-CAAE 20528519.8.0000.5550). Between January 2020 and December 2024, 79 patients with detectable BCR-ABL transcripts were identified in the HEMOPA Foundation database. Adolescents aged between 12 and 18 years were selected, and their demographic (sex and age) and laboratory (leukocyte count) information were extracted for analysis. Detection of fusion transcripts was performed by Real-Time PCR using the Rotor Gene equipment, with TaqMan probes for specific molecular biomarkers. For quantitative variables, means were calculated, while qualitative variables were described by absolute and percentage frequencies. Results: Among the 79 patients analyzed at the HEMOPA Foundation, 3 (3.8%) had the B3A2 transcript of BCR-ABL, 2 of whom were male and 1 female, with a mean age of 14 years. The mean leukocyte count among these 3 cases was 171,666 leukocytes/mm³. Conclusion: The frequency of adolescents with detectable B3A2 transcript was relatively low in the studied population. A predominance of males was observed among the identified cases. The mean age of 14 years reinforces the importance of investigating CML in adolescence. The high mean leukocyte count suggests a significant proliferative burden in the patients. These findings highlight the need for early diagnostic attention in adolescents with suspected hematological changes. Molecular characterization, such as identification of B3A2, assists in diagnosis and therapeutic planning. Additional studies are recommended to assess the clinical impact of the B3A2 transcript in this age group.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
